TY - JOUR
T1 - Vascular Targeting in Photodynamic Occlusion of Subretinal Vessels
AU - Schmidt-Erfurth, Ursula
AU - Hasan, Tayyaba
AU - Gragoudas, Evangelos
AU - Michaud, Norm
AU - Flotte, Thomas J.
AU - Birngruber, Reginald
N1 - Funding Information:
Originally received: December 2, 1993. Revision accepted: May 23, 1994. I Wellman laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston. 2 Retina Department, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston. 3 Augenklinik der Medizinischen Augenklinik zu Liibeck, Liibeck, Germany. 4 Medizinisches laserzentrum Liibeck, Liibeck, Germany. Presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, May 1993. Supported by a Fight-for-Sight Grant in Aid no. GA 91025 and a fellowship of the German Research Council. Each author states that she/he has no proprietary interest in the development of marketing of any commercial product mentioned in this article or competing products.
PY - 1994
Y1 - 1994
N2 - Purpose: To evaluate the potential of photodynamic therapy (PDT) using benzoporphyrin derivative (BPD) for occlusion of subretinal neovascular membranes, the authors studied efficiency and collateral damage of PDT-induced photothrombosis in the rabbit choriocapillary layer. Method: Benzoporphyrin derivative, a new photosensitizer, currently in clinical trials for tumor therapy, was used. Low-density lipoprotein served as a carrier to enhance selective targeting of vascular endothelial cells. Results: Complete choriocapillary occlusion was achieved at a BPD dose of 2 mg/ kg and a radiant exposure as low as 10 J/cm2. When PDT was performed 3 hours after BPD application, damage to the neural retina was minimal. Only inner photoreceptor segments showed mitochondrial swelling probably secondary to choroidal ischemia. Bruch's membrane remained intact. Retinal pigment epithelium was invariably damaged as seen with other photosensitizers. Conclusion: Compared with photocoagulation BPD-PDT allows endothelial-bound intraluminal photothrombosis, sparing important structures such as neural retina and Bruch's membrane. It may thus provide a more selective treatment of juxtafoveal and subfoveal neovascular membranes.
AB - Purpose: To evaluate the potential of photodynamic therapy (PDT) using benzoporphyrin derivative (BPD) for occlusion of subretinal neovascular membranes, the authors studied efficiency and collateral damage of PDT-induced photothrombosis in the rabbit choriocapillary layer. Method: Benzoporphyrin derivative, a new photosensitizer, currently in clinical trials for tumor therapy, was used. Low-density lipoprotein served as a carrier to enhance selective targeting of vascular endothelial cells. Results: Complete choriocapillary occlusion was achieved at a BPD dose of 2 mg/ kg and a radiant exposure as low as 10 J/cm2. When PDT was performed 3 hours after BPD application, damage to the neural retina was minimal. Only inner photoreceptor segments showed mitochondrial swelling probably secondary to choroidal ischemia. Bruch's membrane remained intact. Retinal pigment epithelium was invariably damaged as seen with other photosensitizers. Conclusion: Compared with photocoagulation BPD-PDT allows endothelial-bound intraluminal photothrombosis, sparing important structures such as neural retina and Bruch's membrane. It may thus provide a more selective treatment of juxtafoveal and subfoveal neovascular membranes.
UR - http://www.scopus.com/inward/record.url?scp=0028566497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028566497&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(13)31079-3
DO - 10.1016/S0161-6420(13)31079-3
M3 - Article
C2 - 7997334
AN - SCOPUS:0028566497
SN - 0161-6420
VL - 101
SP - 1953
EP - 1961
JO - Ophthalmology
JF - Ophthalmology
IS - 12
ER -